Doyle, Ralph T.
Amarin (United States)
17 papers on CoChatORCID 0000-0003-4068-7778
Most cited papers
- Verified
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · New England Journal of Medicine
Fatty Acid Research and HealthLipoproteins and Cardiovascular Health
Cited by 3,317
- Verified
Efficacy and tolerability of adding prescription Omega-3 fatty acids 4 g/d to Simvastatin 40 mg/d in hypertriglyceridemic patients: An 8-week, randomized, double-blind, placebo-controlled study
Davidson, M. H., Stein, E. A., Bays, H. E., Maki, K. C., Doyle, R. T., Shalwitz, R. A., Ballantyne, C. M., & Ginsberg, H. N. (2007) · Clinical Therapeutics
Lipoproteins and Cardiovascular HealthFatty Acid Research and Health
Cited by 385
- Verified
Effects of Icosapent Ethyl on Total Ischemic Events
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · Journal of the American College of Cardiology
Fatty Acid Research and HealthLipoproteins and Cardiovascular Health
Cited by 259
- Verified
Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial
Bhatt, D. L., Steg, P. G., Brinton, E. A., Jacobson, T. A., Miller, M., Tardif, J., Ketchum, S. B., Doyle, R. T., Murphy, S. A., Soni, P. N., et al. (2017) · Clinical Cardiology
Fatty Acid Research and HealthLipoproteins and Cardiovascular Health
Cited by 183
- Verified
REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States
Bhatt, D. L., Miller, M., Brinton, E. A., Jacobson, T. A., Steg, P. G., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2020) · Circulation
Fatty Acid Research and HealthLipoproteins and Cardiovascular Health
Cited by 136
- Verified
Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction
Gaba, P., Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Juliano, R. A., Jiao, L., Doyle, R. T., et al. (2022) · Journal of the American College of Cardiology
Fatty Acid Research and HealthLipoproteins and Cardiovascular Health
Cited by 61
- Verified
Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses
Peterson, B. E., Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Juliano, R. A., Jiao, L., Doyle, R. T., et al. (2021) · Circulation
Fatty Acid Research and HealthLipoproteins and Cardiovascular Health
Cited by 57
- Verified
Effects of Prescription Omega-3-Acid Ethyl Esters on Non—High-Density Lipoprotein Cholesterol When Coadministered With Escalating Doses of Atorvastatin
Bays, H. E., McKenney, J., Maki, K. C., Doyle, R. T., Carter, R. N., & Stein, E. (2010) · Mayo Clinic Proceedings
Fatty Acid Research and HealthLipoproteins and Cardiovascular Health
Cited by 54
- Verified
Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies
Ballantyne, C. M., Bays, H. E., Philip, S., Doyle, R. T., Braeckman, R. A., Stirtan, W. G., Soni, P. N., & Juliano, R. A. (2016) · Atherosclerosis
Fatty Acid Research and HealthLipoproteins and Cardiovascular Health
Cited by 52
- Verified
Effects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemic subjects
Davidson, M. H., Bays, H. E., Stein, E., Maki, K. C., Shalwitz, R. A., & Doyle, R. (2006) · Clinical Cardiology
Lipoproteins and Cardiovascular HealthLipid metabolism and disorders
Cited by 51
- Verified
Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies
Ballantyne, C. M., Bays, H. E., Braeckman, R. A., Philip, S., Stirtan, W. G., Doyle, R. T., Soni, P. N., & Juliano, R. A. (2016) · Journal of Clinical Lipidology
Fatty Acid Research and HealthLipoproteins and Cardiovascular Health
Cited by 47
- Verified
Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study)
Ballantyne, C. M., Braeckman, R. A., Bays, H. E., Kastelein, J. J., Otvos, J. D., Stirtan, W. G., Doyle, R. T., Soni, P. N., & Juliano, R. A. (2015) · Journal of Clinical Lipidology
Fatty Acid Research and HealthLipoproteins and Cardiovascular Health
Cited by 46
- Verified
Icosapent ethyl: Eicosapentaenoic acid concentration and triglyceride-lowering effects across clinical studies
Bays, H. E., Ballantyne, C. M., Doyle, R. T., Juliano, R. A., & Philip, S. (2016) · Prostaglandins & Other Lipid Mediators
Fatty Acid Research and HealthLipid metabolism and disorders
Cited by 43
- Verified
Prescription Omega-3 Fatty Acid as an Adjunct to Fenofibrate Therapy in Hypertriglyceridemic Subjects
Roth, E. M., Bays, H. E., Forker, A. D., Maki, K. C., Carter, R., Doyle, R. T., & Stein, E. A. (2009) · Journal of Cardiovascular Pharmacology
Fatty Acid Research and HealthLipid metabolism and disorders
Cited by 32
- Verified
Cardiovascular benefits of icosapent ethyl in patients with and without atrial fibrillation in REDUCE-IT
Olshansky, B., Bhatt, D. L., Miller, M., Steg, P. G., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., et al. (2023) · Journal of the American Heart Association
Fatty Acid Research and HealthAtrial Fibrillation Management and Outcomes
Cited by 29
- Verified
Lipid effects of icosapent ethyl in women with diabetes mellitus and persistent high triglycerides on statin treatment: ANCHOR trial subanalysis
Brinton, E. A., Ballantyne, C. M., Guyton, J. R., Philip, S., Doyle, R. T., Juliano, R. A., & Mosca, L. (2018) · Journal of Women's Health
Fatty Acid Research and HealthLipoproteins and Cardiovascular Health
Cited by 13
- Verified
Effectiveness of icosapent ethyl on first and total cardiovascular events in patients with metabolic syndrome, but without diabetes: REDUCE-IT MetSyn
Miller, M., Bhatt, D. L., Brinton, E. A., Jacobson, T. A., Steg, P. G., Pineda, A. L., Ketchum, S. B., Doyle, R. T., Tardif, J.-C., & Ballantyne, C. M. (2023) · European Heart Journal Open
Fatty Acid Research and HealthLipoproteins and Cardiovascular Health
Cited by 11
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free